Literature DB >> 21245140

SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.

Gabriel Bretones1, Juan C Acosta, Juan M Caraballo, Nuria Ferrándiz, M Teresa Gómez-Casares, Marta Albajar, Rosa Blanco, Paula Ruiz, Wen-Chun Hung, M Pilar Albero, Ignacio Perez-Roger, Javier León.   

Abstract

SKP2 is the ubiquitin ligase subunit that targets p27(KIP1) (p27) for degradation. SKP2 is induced in the G(1)-S transit of the cell cycle, is frequently overexpressed in human cancer, and displays transformation activity in experimental models. Here we show that MYC induces SKP2 expression at the mRNA and protein levels in human myeloid leukemia K562 cells with conditional MYC expression. Importantly, in these systems, induction of MYC did not activate cell proliferation, ruling out SKP2 up-regulation as a consequence of cell cycle entry. MYC-dependent SKP2 expression was also detected in other cell types such as lymphoid, fibroblastic, and epithelial cell lines. MYC induced SKP2 mRNA expression in the absence of protein synthesis and activated the SKP2 promoter in luciferase reporter assays. With chromatin immunoprecipitation assays, MYC was detected bound to a region of human SKP2 gene promoter that includes E-boxes. The K562 cell line derives from human chronic myeloid leukemia. In a cohort of chronic myeloid leukemia bone marrow samples, we found a correlation between MYC and SKP2 mRNA levels. Analysis of cancer expression databases also indicated a correlation between MYC and SKP2 expression in lymphoma. Finally, MYC-induced SKP2 expression resulted in a decrease in p27 protein in K562 cells. Moreover, silencing of SKP2 abrogated the MYC-mediated down-regulation of p27. Our data show that SKP2 is a direct MYC target gene and that MYC-mediated SKP2 induction leads to reduced p27 levels. The results suggest the induction of SKP2 oncogene as a new mechanism for MYC-dependent transformation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245140      PMCID: PMC3059036          DOI: 10.1074/jbc.M110.165977

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.

Authors:  Juan C Acosta; Nuria Ferrándiz; Gabriel Bretones; Verónica Torrano; Rosa Blanco; Carlos Richard; Brenda O'Connell; John Sedivy; M Dolores Delgado; Javier León
Journal:  Mol Cell Biol       Date:  2008-10-06       Impact factor: 4.272

2.  BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.

Authors:  Enrique J Andreu; Elisa Lledó; Enric Poch; Carmen Ivorra; M Pilar Albero; José Angel Martínez-Climent; Cristina Montiel-Duarte; José Rifón; Javier Pérez-Calvo; Cristina Arbona; Felipe Prósper; Ignacio Pérez-Roger
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

3.  Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.

Authors:  C Grandori; J Mac; F Siëbelt; D E Ayer; R N Eisenman
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

Review 4.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

Review 5.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

6.  p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells.

Authors:  María J Muñoz-Alonso; Juan C Acosta; Carlos Richard; M Dolores Delgado; John Sedivy; Javier León
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

7.  Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays.

Authors:  Jung-whan Kim; Karen I Zeller; Yunyue Wang; Anil G Jegga; Bruce J Aronow; Kathryn A O'Donnell; Chi V Dang
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

Authors:  Anupriya Agarwal; Thomas G P Bumm; Amie S Corbin; Thomas O'Hare; Marc Loriaux; Jonathan VanDyke; Stephanie G Willis; Jutta Deininger; Keiichi I Nakayama; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

9.  A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.

Authors:  Zirong Li; Sara Van Calcar; Chunxu Qu; Webster K Cavenee; Michael Q Zhang; Bing Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

Review 10.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

View more
  40 in total

Review 1.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

2.  N-myc regulates growth and fiber cell differentiation in lens development.

Authors:  Gabriel R Cavalheiro; Gabriel E Matos-Rodrigues; Yilin Zhao; Anielle L Gomes; Deepti Anand; Danilo Predes; Silmara de Lima; Jose G Abreu; Deyou Zheng; Salil A Lachke; Ales Cvekl; Rodrigo A P Martins
Journal:  Dev Biol       Date:  2017-07-14       Impact factor: 3.582

3.  Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Authors:  Kamonwan Fish; Jia Chen; Richard Longnecker
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

4.  Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells.

Authors:  Hsin-Ying Hsieh; Jeng-Jer Shieh; Chun-Jung Chen; Mu-Yun Pan; Shu-Yi Yang; Shin-Chang Lin; Jo-Shu Chang; Alan Yueh-Luen Lee; Chia-Che Chang
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Mammalian alteration/deficiency in activation 3 (Ada3) is essential for embryonic development and cell cycle progression.

Authors:  Shakur Mohibi; Channabasavaiah Basavaraju Gurumurthy; Alo Nag; Jun Wang; Sameer Mirza; Yousaf Mian; Meghan Quinn; Bryan Katafiasz; James Eudy; Sanjit Pandey; Chittibabu Guda; Mayumi Naramura; Hamid Band; Vimla Band
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 6.  Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

Authors:  Hisham Abdel-Azim; Weili Sun; Lingtao Wu
Journal:  Pharmacol Ther       Date:  2019-08-27       Impact factor: 12.310

Review 7.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

8.  Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.

Authors:  Marco Kramer; Diogo Ribeiro; Marie Arsenian-Henriksson; Thomas Deller; Hermann Rohrer
Journal:  J Neurosci       Date:  2016-10-05       Impact factor: 6.167

9.  FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.

Authors:  Zhichao Mei; Dawei Zhang; Bo Hu; Jing Wang; Xian Shen; Wuhan Xiao
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

Review 10.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.